Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : MDA - Market Direction Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Casaubon who wrote (43831)	3/22/2000 12:29:00 PM
From: Haim R. Branisteanu	Read Replies (1) \| Respond to of 99985

Casaubon, would agree with your expectations of the next wave of drugs, but all this said the anticipated profits in the future ...e.g. 5 to 10 years from now do not justify the lofty price levels of many bio tech companies. If one would like to ride the anticipated prosperity in the drug industry I would stick with the major players who at least proved to deliver cashflow and profits. To get FDA approval and not to have competition on the same treatment is slim, therefore the earning bonanza is quite elusive. It has to do more with the MM profits and insiders cashing in on lofty stock valuation. BWDIK Haim